O van Tellingen
Overview
Explore the profile of O van Tellingen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
2704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuil L, Seigers R, Loos M, de Gooijer M, Compter A, Boogerd W, et al.
Heliyon
. 2024 May;
10(9):e29947.
PMID: 38707355
Whole brain radiotherapy (WBRT) is used to improve tumor control in patients with primary brain tumors, or brain metastasis from various primary tumors to improve tumor control. However, WBRT can...
2.
Kroon M, van Laarhoven H, Swart E, Kemper E, van Tellingen O
Heliyon
. 2023 May;
9(5):e15540.
PMID: 37131436
Background: The spice curcumin is supposed to have many different beneficial health effects. To understand the complete pharmacokinetics of curcumin we need an analytical method to determine curcumin and its...
3.
Seigers R, Loos M, van Tellingen O, Boogerd W, Smit A, Schagen S
Behav Brain Res
. 2015 Nov;
299:19-26.
PMID: 26602283
Cognitive deficit is a frequently reported side-effect of adjuvant chemotherapy. A large number of animal studies has been performed to examine the neurobiological mechanisms underlying this phenomenon, however, definite conclusions...
4.
Milojkovic Kerklaan B, van Tellingen O, Huitema A, Beijnen J, Boogerd W, Schellens J, et al.
J Neurol
. 2015 Oct;
263(3):428-40.
PMID: 26477024
The treatment for central nervous system metastases of solid tumors and gliomas is limited as the blood-brain barrier (BBB) is an obstacle to systemic therapy. Here, we review the physiochemical...
5.
van Tellingen O, Yetkin-Arik B, de Gooijer M, Wesseling P, Wurdinger T, de Vries H
Drug Resist Updat
. 2015 Mar;
19:1-12.
PMID: 25791797
Gliomas are the most common primary brain tumors. Particularly in adult patients, the vast majority of gliomas belongs to the heterogeneous group of diffuse gliomas, i.e. glial tumors characterized by...
6.
Seigers R, Loos M, van Tellingen O, Boogerd W, Smit A, Schagen S
Psychopharmacology (Berl)
. 2014 Jun;
232(1):17-37.
PMID: 24894481
Rationale And Objectives: Adjuvant chemotherapy is associated with changes in cognition in a subgroup of cancer patients. Chemotherapy is generally given as a combination of cytotoxic agents, which makes it...
7.
Seigers R, Schagen S, van Tellingen O, Dietrich J
Brain Imaging Behav
. 2013 Aug;
7(4):453-9.
PMID: 23949877
Cognitive impairment is a potential long-term side effect of adjuvant chemotherapy that can have a major impact on the quality of life of cancer survivors. There is a growing number...
8.
Borovski T, Beke P, van Tellingen O, Rodermond H, Verhoeff J, Lascano V, et al.
Oncogene
. 2012 May;
32(12):1539-48.
PMID: 22614016
Glioblastoma multiforme (GBM) is a devastating disease with high mortality and poor prognosis. Cancer stem cells (CSCs) have recently been defined as a fraction of tumor cells highly resistant to...
9.
Koolen S, van Waterschoot R, van Tellingen O, Schinkel A, Beijnen J, Schellens J, et al.
J Clin Pharmacol
. 2011 Apr;
52(3):370-80.
PMID: 21505085
Intravenously administered docetaxel is approved for the treatment of various types of cancer. An oral regimen, in combination with ritonavir, is being evaluated in clinical trials. The pharmacokinetics of docetaxel...
10.
Oostendorp R, Buckle T, Lambert G, Garrigue J, Beijnen J, Schellens J, et al.
Invest New Drugs
. 2010 Apr;
29(5):768-76.
PMID: 20390333
The anticancer drug paclitaxel is formulated for i.v. administration in a mixture of Cremophor EL and ethanol.Its oral bioavailability is very low due to the action of P-glycoproteinin the gut...